The Pharmaceutical Industry in Nigeria: Drug Accessibility, Affordability and Competitiveness in the Economy.

The study focuses on reviewing factors that influence accessibility, affordability, efficiency in Nigeria’s pharmaceutical industry and its impact on healthcare delivery. Despite Nigeria's increasing population coupled with a high disease burden, it imports most of its drugs from India and China since its own pharmaceutical sector is not self-sufficient. The study noted certain difficulties such as poor infrastructure, inflation, exchange rate volatility, poverty and weak regulatory structure in the health sector made it tough for people to get access and afford basic medicines. The study deployed a semi-log regression to see how accessibility and affordability of medicines interact with the capacity of the pharmaceutical sector in the Nigerian economy. Findings from the study revealed significant interrelatedness between level of access to essential medicines and the pharmaceutical industry contribution to GDP; other variables, such as costs of Malaria treatments, minimum wage, and inflation, showed weak or no statistical impact on the response variable. In conclusion, the study suggests that the Federal government should discontinue the NHIS programme and allow the private sector to take over to free up resources and strengthen local pharmaceutical production, it therefore recommends that stakeholders should strengthen regulatory measures to make medications affordable in Nigeria to guarantee better health outcomes for a stronger economy.